A Gut Bacteria Byproduct May Make Strokes More Severe, Study Finds

If you've ever wondered whether your gut has anything to do with how badly you'd be hit by a stroke, a new study gives a specific, early answer. Researchers have identified a compound made by common gut bacteria that appears to prime the immune system for worse brain damage before a stroke happens. The work, published September 29, 2026 in the journal Cell, traces the effect to one bacterial byproduct and one immune receptor; blocking that receptor in mice meant strokes did measurably less damage. It is still animal and observational evidence, not a treatment, but it adds gut bacteria to the list of things that may quietly shape stroke severity.

Key takeaways

• A gut bacteria byproduct called indole, made from the amino acid tryptophan, worsened strokes in mice by activating an immune receptor called AHR in gut dendritic cells.
• Blocking that pathway, either by deleting the receptor or with a drug, shrank brain injury in mice, and the protection depended on regulatory T cells (Tregs).
• Stroke patients carried more indole-producing bacteria than healthy people, and among 148 patients followed for 90 days, higher levels of the bacterial gene behind indole production trended toward worse recovery.
• The catch: the causal proof comes entirely from mice; the human data is correlational and no treatment was tested in people.

Indole-Producing Gut Bacteria Linked to Worse Stroke Damage

A compound called indole, made when certain gut bacteria break down tryptophan (an amino acid found in protein-rich foods), appears to make strokes more severe by switching on an immune pathway beforehand. A team led by Corinne Benakis at LMU Munich's Institute for Stroke and Dementia Research found that mice who went on to have more severe strokes carried more indole-producing Escherichia coli (E. coli) and higher indole levels in their small intestine. To test cause and effect, the researchers colonized mice beforehand with normal, indole-making E. coli or an engineered strain missing the gene (tnaA) needed to make indole. Mice carrying the indole-making bacteria developed larger brain lesions (infarcts) and worse neurological scores than mice carrying the indole-free strain. Giving mice indole directly by mouth for two weeks before a stroke reproduced the same harm alone, while a related tryptophan byproduct, indoxyl sulfate, had no effect, singling out indole as the culprit.

Stroke Risk Groups Have a Stake in This Pathway

This finding matters most to people who already carry elevated stroke risk, not only to those who've already had one. Someone in the United States has a stroke roughly every 40 seconds, and most are ischemic strokes, the blocked-vessel type modeled here. People managing type 2 diabetes, obesity, or high blood pressure, all established, independent risk factors for stroke, have a direct stake: the indole-producing bacterial signature was already elevated in people with obesity and type 2 diabetes, even without any stroke history, versus healthy controls. Whatever primes this pathway may already be present in people most likely to eventually have a stroke, not something that appears only afterward.

Mouse Genetics and a 148-Patient Cohort Built the Case

The researchers combined causal mouse experiments with an observational analysis of stroke patients. In mice, they used a standard ischemic stroke model (temporary blockage of a brain artery) and classified animals as moderate or severe three days later, based on infarct size, weight loss, and neurological symptoms; 43% developed severe strokes. To find which immune cells mattered, they bred mice lacking the aryl hydrocarbon receptor (AHR), a protein that senses bacterial and dietary chemicals including indole, in specific immune cell types. Deleting AHR only in dendritic cells (CD11c+ cells, which sample the gut lining and instruct other immune responses) produced markedly smaller strokes; deleting it in T cells, neutrophils, or macrophages did not. They confirmed this with a drug that blocks AHR chemically, and with fecal transplants: gut bacteria from three mildly and three severely affected stroke patients were transferred into separate groups of mice before those mice had their own strokes, building on earlier work from the same research group on gut bacteria and stroke outcome. On the human side, the team analyzed stool taken from stroke patients within the first week after onset, then tracked 148 of them for 90 days against how much indole-producing bacteria they carried.

What This Could Mean If You Manage Stroke Risk

This is not a reason to start a probiotic, avoid high-protein foods, or ask for an antibiotic; the researchers tested no such intervention in people. It does suggest gut bacteria composition, specifically how much indole-producing bacteria someone carries, may be one of several factors shaping how much damage a stroke causes, alongside established risks like blood pressure and clotting history. If you already manage diabetes or obesity, this is one more reason to keep it controlled with your doctor, not because this study proves gut bacteria change outcomes in people, but because it offers a plausible biological link between those conditions and the immune state a stroke would meet in the gut. It's reasonable to raise gut health in a broader stroke-prevention conversation, but there is no specific test, drug, or diet here to request yet.

Key Caveat: Human Evidence Is Still Correlational

The central limitation is one the authors state directly: every causal experiment, bacterial colonization, indole dosing, genetic deletion, was done in mice, and only in male mice, since AHR biology is known to differ by sex elsewhere. The human portion is observational: researchers measured which bacteria stroke patients already carried and compared that to outcomes, but never tested whether changing those bacteria would change anyone's recovery. Even that human association was modest. The bacterial gene behind indole production (tnaA) trended toward predicting worse 90-day outcomes only after statistically accounting for age, high blood pressure, and initial stroke severity, and that trend (odds ratio 2.23) narrowly missed standard significance (p = 0.061); plain E. coli abundance lost its own association with outcome once those factors were accounted for.

What Comes Next for This Gut-Brain Target

The authors describe microbial tryptophan metabolism, the process bacteria use to turn a dietary amino acid into indole, as "a tractable therapeutic target," meaning a drug or microbiome-based approach could plausibly interrupt it later. The team has made its sequencing data and analysis code public, and the next step they call for directly is validating the human findings in larger, prospective cohorts that track gut bacteria before a stroke happens rather than only after. No clinical trial of an AHR-blocking drug or microbiome treatment for stroke has been announced, and with the human signal still a trend rather than proof, that is unlikely to change quickly. What the study does provide is a specific, named target for future research: AHR signaling in gut dendritic cells.

Common Questions

What is indole, and why does it matter for stroke? Indole is a compound certain gut bacteria, including some E. coli strains, make by breaking down tryptophan, an amino acid from dietary protein. This study found indole can activate an immune pathway, through a receptor called AHR, that made strokes worse in mice.

Is this relevant to humans, or only mice? Both, with a caveat. The experiments proving indole worsens stroke outcomes were done in mice, but stroke patients also carried more indole-producing bacteria than healthy people, and those with worse 90-day recovery tended to carry more of the bacterial gene responsible for making it. The human part is correlational, not causal.

Should I take a probiotic or change my diet to lower my stroke risk because of this? No. The study did not test any probiotic, supplement, or dietary change in people, and the researchers made no such recommendation. This is a mechanism worth further research, not a treatment that is ready to use.

What is the aryl hydrocarbon receptor (AHR)? AHR is a receptor in many cells, including the dendritic cells that patrol the gut lining, that senses chemicals from bacteria and diet, including indole, and changes how those cells behave, here toward a state linked to worse stroke outcomes.

References

1. Rosa Delgado Jiménez, Alexandria Ruggles, Mujeeb Adekunle Adedokun, et al. (2026). Gut microbiota primes stroke severity via the AHR in intestinal dendritic cells. Cell. https://doi.org/10.1016/j.cell.2026.09.013
2. Stroke Facts | cdc.gov. cdc.gov. https://www.cdc.gov/stroke/data-research/facts-stats
3. Andrew B Mitchell, John W Cole, Patrick F McArdle, Yu-Ching Cheng, Braxton D Mitchell, Steven J Kittner (2014). Abstract W P152: Obesity Increases Risk of Ischemic Stroke in Young Adults. Stroke. https://doi.org/10.1161/str.45.suppl_1.wp152